Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 29th Annual ROTH Conference. Chief Executive Officer Mary Szela is scheduled to present on Tuesday, March 14, 2017 at 2:00 p.m. PDT (5:00 p.m. EDT).
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
